
How does long-term exercise slow ageing? Chinese scientists have an answer
By looking at the key molecular pathways that help to reshape the physiology of the human body and delay ageing through exercise, they revealed that betaine acts as a core messenger in this process. It prevents inflammation and the ageing of multiple organs by targeting and inhibiting an enzyme called TBK1.
The findings not only shed light on the mechanism behind the anti-ageing effects of exercise, but also suggest possible anti-ageing strategies by simulating exercise, according to the joint team from the Chinese Academy of Sciences' Institute of Zoology and Beijing Institute of Genomics.
Led by Liu Guanghui and Qu Jing from the zoology institute and Zhang Weiqi from the genomics institute, the researchers reported their findings in the peer-reviewed journal Cell on June 25.
Nutrition, exercise, sleep and stress management are widely considered the four pillars of health, including by institutions such as the World Health Organization. Much research has shown that exercise can powerfully influence the ageing process.
However, the Chinese researchers noted the fundamental molecular mechanisms between exercise and longevity remained poorly understood, as did other questions such as how various exercise patterns differed in their beneficial effects on health.
To solve this puzzle, they launched a study in 2019 to investigate the effects of exercise on health in both mice and humans. By 2023, they had made progress, having systematically analysed the cellular and molecular responses of 14 organ tissues to long-term aerobic exercise in young and aged mice.
Building on these findings, the researchers continued their study with human participants.
In this phase, 13 healthy male volunteers were recruited. The participants were required to run 5km (3.1 miles) in 40 minutes and then take up long-term regular exercise for 25 days.
After that, the researchers collected blood and faecal samples from the participants at various intervals, as well as health examination data. They later used a range of analytical methods, including plasma proteomics analysis, to study the samples and establish a research framework.
The six-year research project identified the kidney as 'the key responsive organ' for exercise and found that betaine, its product of metabolism, serves as the core molecular messenger for slowing ageing.
Even more significant for real-life applications, the team discovered that supplementing this compound 'can precisely mimic the benefits of long-term exercise', according to the authors.
In experiments on aged mice, the team found that oral administration of betaine could extend their healthy lifespan, significantly improving functional indicators such as metabolic capacity, kidney function and motor coordination, while also reducing depressive-like behaviour and improving cognitive function.
The team pointed out that betaine's efficacy at low doses and its good safety profile 'offer a potential anti-ageing strategy for the elderly', who are unable to undertake long-term intense exercise.
Furthermore, they said the study pioneered a new research paradigm capable of 'translating complex physiological effects into quantifiable, actionable chemical language', opening up a new avenue for future ageing intervention studies. - SOUTH CHINA MORNING POST
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Sun
4 minutes ago
- The Sun
Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
HONG KONG SAR - Media OutReach Newswire - 25 July 2025 – MicroPort Scientific Corporation (Stock Code: 'MicroPort') announced that Shanghai Healthcare M&A Fund ('SHMAF'), a fund managed by SIIC Capital, a subsidiary of SIIC Group, has entered into a share purchase agreement to acquire 135,335,204 shares in MicroPort held by Otsuka Medical Devices Co., Ltd. Through this transaction, SHMAF will become a strategic shareholder in MicroPort, underscoring its role as a state-backed, professionally operated platform that is creating value and empowering, stabilizing, developing, and reshaping leading biopharmaceutical companies in China. As a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive resources. Introducing a strategic shareholder to drive growth momentum. The transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its operations. Optimizing resource allocation to unlock synergistic value. MicroPort has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive advantages. Enhancing ecosystem to enhance anchor company value. MicroPort's product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device industry. This transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical industry.


Malay Mail
17 minutes ago
- Malay Mail
Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
HONG KONG SAR - Media OutReach Newswire - 25 July 2025 – MicroPort Scientific Corporation (Stock Code: "MicroPort") announced that Shanghai Healthcare M&A Fund ("SHMAF"), a fund managed by SIIC Capital, a subsidiary of SIIC Group, has entered into a share purchase agreement to acquire 135,335,204 shares in MicroPort held by Otsuka Medical Devices Co., Ltd. Through this transaction, SHMAF will become a strategic shareholder in MicroPort, underscoring its role as a state-backed, professionally operated platform that is creating value and empowering, stabilizing, developing, and reshaping leading biopharmaceutical companies in a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical #SIICCapital #MicroPort #SHMAF The issuer is solely responsible for the content of this announcement. About MicroPort Scientific Corporation Founded in 1998 and headquartered in Shanghai's Zhangjiang, MicroPort Scientific Corporation is a leading domestic innovative high-end medical device group. It began by breaking the import monopoly in the cardiovascular stent field, and after 26 years of innovative development, its business has expanded to areas including rhythm management, orthopaedics, cardiovascular intervention, aortic and peripheral vascular intervention, neurovascular intervention, heart valves, surgical robots, and surgical medical devices. By the end of 2024, MicroPort operated in over 20,000 hospitals across 100 countries and regions worldwide, providing more than 600 solutions for patients covering over 200 diseases. MicroPort has incubated 6 A-share and Hong Kong-listed companies, owns 9 specialized and sophisticated SMEs, 4 technology giant enterprises, and 16 national high-tech enterprises, making it an outstanding representative of Shanghai's technological innovation and industrial transformation. About SIIC Capital As the active fund management platform under SIIC Group, since its establishment, SIIC Capital has been based in Shanghai, connected with Hong Kong, and oriented towards the world, actively exploring investment opportunities in strategic emerging industries such as biomedicine and green environmental protection. Through a multi-currency, full-stage fund matrix layout, it deeply serves national strategies and the construction of biomedicine highlands.

Malay Mail
3 hours ago
- Malay Mail
Amazon shuts Shanghai AI lab amid rising US-China tech tensions
SHANGHAI, July 25 — US tech giant Amazon has shut down its artificial intelligence research lab in Shanghai, a source with direct knowledge of the matter confirmed to AFP. News that the lab, part of cloud division Amazon Web Services (AWS), has closed comes with AI at the forefront of a tech race between China and the US. In a screenshot of a WeChat post widely circulated on Chinese social media this week, Wang Minjie, a scientist at the lab, said its disbanding was 'due to the strategic adjustment between China and the United States'. AWS announced job cuts across its operations last week, with some reports putting the losses at hundreds. Amazon declined to confirm the Shanghai lab's closure directly when contacted by AFP. 'We've made the difficult business decision to eliminate some roles across particular teams in AWS,' spokesman Brad Glasser said in a similar statement to the one released in response to the broader job losses. 'These decisions are necessary as we continue to invest, hire, and optimise resources to deliver innovation for our customers.' A dedicated AWS China webpage for the lab seen on Wednesday by AFP was no longer accessible today. According to an archive of the page, the lab was established in autumn 2018, with part of its remit to 'actively foster collaboration with the research community'. Other US tech firms such as Microsoft and IBM have scaled back their research divisions in China recently, as the tech competition between Washington and Beijing shows no sign of abating. — AFP